Tabula Rasa HealthCare Stock Price, News & Analysis (NASDAQ:TRHC)

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tabula Rasa HealthCare in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TRHC shares.
View TRHC analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 1 year price objectives for Tabula Rasa HealthCare's stock. Their TRHC share price targets range from $6.00 to $10.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests that the stock has a possible downside of 23.8%.
View analysts price targets for TRHC or view top-rated stocks among Wall Street analysts.

Tabula Rasa HealthCare's stock was trading at $4.95 at the beginning of 2023. Since then, TRHC stock has increased by 112.1% and is now trading at $10.50.
View the best growth stocks for 2023 here.

Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.15. The business had revenue of $86.60 million for the quarter, compared to the consensus estimate of $88.54 million. The business's revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.35) earnings per share.

24 employees have rated Tabula Rasa HealthCare Chief Executive Officer Calvin H. Knowlton, BScPharm, MDiv, PhD on Glassdoor.com. Calvin H. Knowlton, BScPharm, MDiv, PhD has an approval rating of 91% among the company's employees. This puts Calvin H. Knowlton, BScPharm, MDiv, PhD in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tabula Rasa HealthCare investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Adobe (ADBE), Micron Technology (MU), Boeing (BA), Salesforce (CRM), Intel (INTC) and Netflix (NFLX).

(TRHC) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,300,000 shares at $13.00-$15.00 per share. Wells Fargo Securities, UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Baird and Stifel were co-managers.

Tabula Rasa HealthCare's stock is owned by a variety of institutional and retail investors. Top institutional investors include Beryl Capital Management LLC (2.19%), Qube Research & Technologies Ltd (1.36%), Gabelli Funds LLC (1.31%), Kennedy Capital Management LLC (1.11%), GABELLI & Co INVESTMENT ADVISERS INC. (0.91%) and EHP Funds Inc. (0.83%). Insiders that own company stock include Andrea Carolan Speers, Brian W Adams, Calvin H Knowlton, Dennis Helling, Gordon Tunstall, Indaba Capital Management, LP, Jan Berger, Michael Greenhalgh, Michael J Purcell, Orsula V Knowlton, Orsula V Knowlton, Samira Beckwith and Thomas Cancro.
View institutional ownership trends.

Shares of TRHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.